A 2026 case report describes a 34-year-old man with obesity and alcohol use disorder whose semaglutide treatment for weight ...

In a subgroup analysis, there was a positive effect in people with obesity, with significant reductions in brain reward center cue reactivity on functional magnetic resonance imaging. (HealthDay News) ...

Accumulating scientific evidence and industry interest from Eli Lilly, Altimmune and startup Baseline Therapeutics is driving further research on the therapeutic potential of GLP-1 receptor agonists ...

Anti-obesity drugs such as semaglutide (Ozempic, Wegovy) are also promising for the treatment of alcohol use disorder and alcohol-associated liver disease, as growing evidence suggests they reduce the ...

Data were included for 262 adults with a body mass index greater than or equal to 27kg/m2 who were initiated on liraglutide or semaglutide. HealthDay News — Glucagon-like peptide-1 receptor agonists ...

What happens in the brain when we drink alcohol? Scientists have taken a significant step toward answering this question by identifying a protein called TMEM132B as a key regulator of alcohol’s ...

(Boston)—Alcohol use is widespread and alcohol use disorder (AUD) causes substantial harm. AUD affects 29 million individuals and causes more than 140,000 deaths annually in the U.S. alone.

Recent studies continue to support a decades-old drug as an alternative means of reducing alcohol consumption. The prescription opioid antagonist, called naltrexone, was first approved by the FDA to ...

Reductions in alcohol intake noted in high and low consumers; no significant difference seen in percentage reductions for men and women. (HealthDay News) — Glucagon-like peptide-1 receptor agonists ...

However, authors caution there is little high-quality evidence. (HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some ...